Abstract

Immune-stimulatory ligands, such as major histocompatibility complex molecules and the T-cell costimulatory ligand CD86, are central to productive immunity. Endogenous mammalian membrane-associated RING-CHs (MARCH) act on these and other targets to regulate antigen presentation and activation of adaptive immunity, whereas virus-encoded homologs target the same molecules to evade immune responses. Substrate specificity is encoded in or near the membrane-embedded domains of MARCHs and the proteins they regulate, but the exact sequences that distinguish substrates from nonsubstrates are poorly understood. Here, we examined the requirements for recognition of the costimulatory ligand CD86 by two different MARCH-family proteins, human MARCH1 and Kaposi's sarcoma herpesvirus modulator of immune recognition 2 (MIR2), using deep mutational scanning. We identified a highly specific recognition surface in the hydrophobic core of the CD86 transmembrane (TM) domain (TMD) that is required for recognition by MARCH1 and prominently features a proline at position 254. In contrast, MIR2 requires no specific sequences in the CD86 TMD but relies primarily on an aspartic acid at position 244 in the CD86 extracellular juxtamembrane region. Surprisingly, MIR2 recognized CD86 with a TMD composed entirely of valine, whereas many different single amino acid substitutions in the context of the native TM sequence conferred MIR2 resistance. These results show that the human and viral proteins evolved completely different recognition modes for the same substrate. That some TM sequences are incompatible with MIR2 activity, even when no specific recognition motif is required, suggests a more complicated mechanism of immune modulation via CD86 than was previously appreciated.

Highlights

  • Cell-surface ligands play crucial roles in controlling adaptive immunity by modulating lymphocyte function both at initial

  • Our results show that MARCH1 very requires a proline at position 254 in the CD86 transmembrane domain (TMD), whereas modulator of immune recognition 2 (MIR2) requires an aspartic acid in the extracellular JM domain, as previously reported in a study using a chimeric model substrate [18]

  • The human CD86 TMD is required for recognition by MARCH1 but not MIR2

Read more

Summary

Introduction

Cell-surface ligands play crucial roles in controlling adaptive immunity by modulating lymphocyte function both at initial. MIR2 requires no specific sequences in the CD86 TMD, because it effectively downregulated CD86 with a PolyVal TMD, yet single amino acid substitutions at many TM positions could impair susceptibility to MIR2 but not MARCH1.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call